KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Gains from Sales and Divestitures: 2011-2025

Historic Gains from Sales and Divestitures for Sarepta Therapeutics (SRPT) over the last 2 years, with Sep 2025 value amounting to $38,050.

  • Sarepta Therapeutics' Gains from Sales and Divestitures fell 60.96% to $38,050 in Q3 2025 from the same period last year, while for Sep 2025 it was $38,050, marking a year-over-year decrease of 60.96%. This contributed to the annual value of $734,922 for FY2024, which is 14.01% up from last year.
  • According to the latest figures from Q3 2025, Sarepta Therapeutics' Gains from Sales and Divestitures is $38,050, which was down 0.00% from $38,050 recorded in Q2 2025.
  • Sarepta Therapeutics' Gains from Sales and Divestitures' 5-year high stood at $734,922 during Q4 2024, with a 5-year trough of $38,050 in Q2 2025.
  • Its 3-year average for Gains from Sales and Divestitures is $292,219, with a median of $97,460 in 2024.
  • As far as peak fluctuations go, Sarepta Therapeutics' Gains from Sales and Divestitures soared by 69.96% in 2021, and later tumbled by 75.33% in 2024.
  • Quarterly analysis of 5 years shows Sarepta Therapeutics' Gains from Sales and Divestitures stood at $276,980 in 2021, then spiked by 40.72% to $389,761 in 2022, then surged by 65.39% to $644,614 in 2023, then rose by 14.01% to $734,922 in 2024, then crashed by 60.96% to $38,050 in 2025.
  • Its Gains from Sales and Divestitures stands at $38,050 for Q3 2025, versus $38,050 for Q2 2025 and $734,922 for Q4 2024.